Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Elpiscience Biopharmaceuticals Inc.

Headquarters: Shanghai, China
Year Founded: 2017
Status: Private

BioCentury | Dec 22, 2021
Product Development

PD-1’s new narrative – a bonanza of innovation

Half the field is stuck in first gear, but a wealth of bispecifics, novel technologies are bringing new energy
BioCentury | Oct 26, 2021
Product Development

What’s next for CRISPR & gene therapy, plus a China Summit Preview

Emerging Company Spotlight: Elpiscience and Rectify
BioCentury | Oct 21, 2021
Emerging Company Profile

Elpiscience builds out global pipeline with CD39 focus

Dual-track strategy includes in-licensing for China market, but focus is on driving wholly-owned pipeline in U.S.
BioCentury | Dec 28, 2019
Financial News

Elpiscience’s $100M series B provides path to IPO

BioCentury | Dec 7, 2018
Financial News

Hillhouse backs Elpiscience's $35M round

BioCentury | Dec 4, 2018
Financial News

Hillhouse backs Elpiscience's $35M round

BioCentury | Apr 26, 2018
Product R&D

Brake for gas

China newco Elpiscience links 4-1BB boost to PD-L1 block in first of 12 programs
Items per page:
1 - 7 of 7